Manifestation of Subclinical Extrapulmonary Tuberculosis after COVID-19 Vaccination as Supraclavicular Lymphadenopathy

Han Gyu Cha; Dong Gyu Kim; Joon Ho Choi

doi:10.3390/vaccines10060964

Manifestation of Subclinical Extrapulmonary Tuberculosis after COVID-19 Vaccination as Supraclavicular Lymphadenopathy

Vaccines (Basel). 2022 Jun 16;10(6):964. doi: 10.3390/vaccines10060964.

Authors

Han Gyu Cha¹, Dong Gyu Kim¹, Joon Ho Choi²

Affiliations

¹ Department of Plastic and Reconstructive Surgery, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon 14584, Korea.
² Department of Nuclear Medicine, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon 14584, Korea.

Abstract

Lymphadenopathy after coronavirus disease 2019 (COVID-19) vaccination is a common side effect that usually resolves within several days to weeks, and only observation is recommended. However, for prolonged lymphadenopathy, other possibilities, including malignancy or other lymphoproliferative diseases, may be considered. Herein, we report the case of a 66-year-old woman who experienced prolonged ipsilateral supraclavicular lymph node enlargement after the second dose of the ChAdOx1 (Oxford-AstraZeneca) COVID-19 vaccine, which was eventually diagnosed as extrapulmonary tuberculosis.

Keywords: COVID-19; lymphadenopathy; tuberculosis; vaccination.

Publication types

Case Reports

Grants and funding

This research received no external funding.